Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene Ciloleucel vs Standard of Care in Relapsed/Refractory Follicular Lymphoma
2024-511594-30-00Phase 3Authorised
- Sponsor
- Kite Pharma
- Start
- Jul 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial in follicular lymphoma (FL) comparing Axicabtagene ciloleucel arm with Standard-of-care arm (2 arms). Primary endpoint: Progression-free survival (PFS). Planned start Jul 2024; status: authorised.
02
Drugs
axicabtagene ciloleucel
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2024-511594-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511594-30-00.